Functional outcomes of repeat kidney resection in patients with cancer recurrence after nephron-sparing surgeries

N. K. Zhumabaev, M. Komarov, A. Klimov, V. Matveev, I. Stilidi
{"title":"Functional outcomes of repeat kidney resection in patients with cancer recurrence after nephron-sparing surgeries","authors":"N. K. Zhumabaev, M. Komarov, A. Klimov, V. Matveev, I. Stilidi","doi":"10.17650/1726-9776-2023-19-4-15-23","DOIUrl":null,"url":null,"abstract":"Aim. To perform comparative analysis of functional outcomes of repeat kidney resection and radical nephrectomy in patients with local cancer recurrence after previous organ-sparing surgeries.Materials and methods. Data on 64 patients who underwent surgical treatment at the Oncourology Department of the N.N. Blokhin National Medical Research Center of Oncology between 2000 and 2022 due to local kidney cancer recurrence after previous nephron-sparing surgeries were retrospectively and prospectively included in the study. Among these, 37 (57.8 %) patients underwent repeat kidney resection (treatment group) and 27 (42.2 %) patients underwent radical nephrectomy (control group). The groups were matched in demographic and clinical characteristics (р >0.05). Median diameter of recurrent tumor in the treatment and control groups was 2.5 and 3.0 cm, respectively (95 % confidence interval 2.0–3.0 cm; Q1–Q3 2.4–4.0 cm). This difference was statistically significant (р = 0.012), but not clinically. Median follow-up duration was 35 (3–131) months (Q1–Q3 13–57 months).Results. Repeat nephron-sparing surgeries correlated with lower decrease in kidney function compared to organ-resecting surgical treatment. In the early postoperative period, decrease in calculated glomerular filtration rate per the CKD-EPI formula compared to baseline after re-resection and nephrectomy was 16 and 32 % (р = 0.010); long-term, it was 8 ± 41 and 45 ± 22 % (р <0.001), respectively. Complication rates in the groups were similar: 21.6 and 29.6 %, respectively (р = 0.563).Conclusion. For local kidney cancer recurrence, repeat resection promotes preservation of kidney function without increased complication rate.","PeriodicalId":216890,"journal":{"name":"Cancer Urology","volume":"17 11","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17650/1726-9776-2023-19-4-15-23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Aim. To perform comparative analysis of functional outcomes of repeat kidney resection and radical nephrectomy in patients with local cancer recurrence after previous organ-sparing surgeries.Materials and methods. Data on 64 patients who underwent surgical treatment at the Oncourology Department of the N.N. Blokhin National Medical Research Center of Oncology between 2000 and 2022 due to local kidney cancer recurrence after previous nephron-sparing surgeries were retrospectively and prospectively included in the study. Among these, 37 (57.8 %) patients underwent repeat kidney resection (treatment group) and 27 (42.2 %) patients underwent radical nephrectomy (control group). The groups were matched in demographic and clinical characteristics (р >0.05). Median diameter of recurrent tumor in the treatment and control groups was 2.5 and 3.0 cm, respectively (95 % confidence interval 2.0–3.0 cm; Q1–Q3 2.4–4.0 cm). This difference was statistically significant (р = 0.012), but not clinically. Median follow-up duration was 35 (3–131) months (Q1–Q3 13–57 months).Results. Repeat nephron-sparing surgeries correlated with lower decrease in kidney function compared to organ-resecting surgical treatment. In the early postoperative period, decrease in calculated glomerular filtration rate per the CKD-EPI formula compared to baseline after re-resection and nephrectomy was 16 and 32 % (р = 0.010); long-term, it was 8 ± 41 and 45 ± 22 % (р <0.001), respectively. Complication rates in the groups were similar: 21.6 and 29.6 %, respectively (р = 0.563).Conclusion. For local kidney cancer recurrence, repeat resection promotes preservation of kidney function without increased complication rate.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
保留肾脏手术后癌症复发患者重复肾脏切除术的功能结果
目的对既往接受过器官保留手术后局部癌症复发的患者接受重复肾切除术和根治性肾切除术的功能结果进行比较分析。本研究回顾性和前瞻性纳入了2000年至2022年期间在尼-尼-布洛金国立肿瘤学医学研究中心肿瘤科接受手术治疗的64名既往肾脏保全手术后局部肾癌复发患者的数据。其中,37 例(57.8%)患者接受了重复肾切除术(治疗组),27 例(42.2%)患者接受了根治性肾切除术(对照组)。两组患者在人口统计学和临床特征方面相匹配(р >0.05)。治疗组和对照组复发肿瘤的中位直径分别为 2.5 厘米和 3.0 厘米(95% 置信区间为 2.0-3.0 厘米;Q1-Q3 为 2.4-4.0 厘米)。这一差异具有统计学意义(р = 0.012),但无临床意义。中位随访时间为 35 (3-131) 个月(Q1-Q3 13-57 个月)。与器官切除手术治疗相比,重复肾小球保留手术与肾功能下降有关。术后早期,根据CKD-EPI公式计算,再次切除和肾切除术后肾小球滤过率与基线相比分别下降16%和32%(р = 0.010);长期分别为8 ± 41%和45 ± 22%(р <0.001)。两组的并发症发生率相似:分别为21.6%和29.6%(р = 0.563)。结论:对于局部肾癌复发,重复切除术有助于保留肾功能,且不会增加并发症发生率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Effectiveness and safety of darolutamide as a component of combination therapy in patients with prostate cancer Biosimilars in the practice of modern oncologist First experience of using Pembroria® medication in patients with disseminated renal cell carcinoma Clinical and economic effectiveness of using immunotherapeutic drugs in patients with urothelial carcinoma in the healthcare system of the Russian Federation Radical cystectomy with extraperitoneal location of an artificial bladder
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1